Herceptin-directed nanoparticles activated by an alternating magnetic field selectively kill HER-2 positive human breast cellsin vitrovia hyperthermia

Abstract

These studies demonstrate Herceptin-directed nanoparticles can selectively kill HER-2(+) cancer cells via hyperthermia after AMF activation.

Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers

“…Although there is little report in the literature that is concerned with the synergistic effect between the herceptin biological therapy and the IOs hyperthermia therapy, several herceptin conjugated nanoparticles or liposomes have been synthesized for enhanced hyperthermia therapy, which have achieved strong better therapeutic effects [39,40]. Our result shows a strong synergistic effects between the bio and the thermo therapies.…”

Perspectives of Breast Cancer Thermotherapies

“…For that, 1 to 2 mg of nanoparticles, 51-53, have been administered either intravenously, 51, 52, or directly to tumors, 53, of typical sizes 100 to 200 mm 3 , 51, 52. Specific targeting of the tumors was achieved by using 111InCh antibody, 51, 52, or anti-HER2 molecules attached either to the nanoparticles, 53-55, or to the liposomes containing the nanoparticles, 56. In order to generate heat, the nanoparticles were exposed to an alternating magnetic field of strength 12-130 mT and frequency of 118-360 kHz during 20-30 minutes, 51-56.…”

c-erbB-2 as a Possible Target for the Use of Magnetic Nanoparticles in Breast Cancer Cells

“…However, the use of an animal model usually presents some variables that cannot be controlled and these can alter the detection as well as the behavior of the tumor cells in vivo. Moreover, other studies used other cell lines (20,22,25) that expressed the c-erbB2 receptor differently and evaluated the presence of bioconjugates by using different techniques, such as TEM, in contrast to the flow cytometry and fluorescence microscopy methods proposed in this study. Our research provides important evidence regarding the ability of the bioconjugates to recognize breast cancer cells expressing high levels of c-erbB2 compared with cell expressing low c-erbB2.…”

“…This study demonstrated that Herceptin coupled to magnetic nanoparticles can selectively kill cancer cells via hyperthermia after AMF activation. [25]. Smith et al (2011) examined the localized delivery of the Affibody (ZHER2-GS-Cys)-conjugated with thermosensitive liposomes (Her2 + Affisomes) by monitoring cellular interactions, intracellular uptake, and hyperthermia-induced effects on drug delivery in HER2 + cell lines.…”